This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06649045 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 712 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | OSA; Overweight or Obesity |
| Interventions | Orforglipron; Placebo |
| Start | Oct 22, 2024 |
| Primary completion | Jul 21, 2026 |
| Study completion | Jul 30, 2026 |
| Results posted | Not yet |
| Registry last updated | Sep 14, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in Apnea-Hypopnea Index (AHI) | Baseline to Week 52 |
7 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 16, 2026. See the trial changes feed for what has changed recently.
More from Eli Lilly and Company
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881432)
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased (Phase 3 NCT07900633)
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881458)
- RENEW-MDD 1: Brenipatide, Phase 3 (NCT07412756)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.